JP2014533698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533698A5 JP2014533698A5 JP2014542536A JP2014542536A JP2014533698A5 JP 2014533698 A5 JP2014533698 A5 JP 2014533698A5 JP 2014542536 A JP2014542536 A JP 2014542536A JP 2014542536 A JP2014542536 A JP 2014542536A JP 2014533698 A5 JP2014533698 A5 JP 2014533698A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- polymer
- poly
- microparticles
- pla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 229920000642 polymer Polymers 0.000 claims description 49
- 239000011859 microparticle Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 33
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 30
- 229920001710 Polyorthoester Polymers 0.000 claims description 28
- 239000002745 poly(ortho ester) Substances 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 24
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- 229920000526 Poly[1,6-bis(p-carboxyphenoxy)hexane] Polymers 0.000 claims description 12
- 102000025171 antigen binding proteins Human genes 0.000 claims description 12
- 108091000831 antigen binding proteins Proteins 0.000 claims description 12
- 229920002988 biodegradable polymer Polymers 0.000 claims description 12
- 239000004621 biodegradable polymer Substances 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 108010081667 aflibercept Proteins 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 229920001610 polycaprolactone Polymers 0.000 claims description 10
- 239000002344 surface layer Substances 0.000 claims description 7
- 229920002732 Polyanhydride Polymers 0.000 claims description 6
- -1 Polyethylene Polymers 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000000527 sonication Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 210000004127 vitreous body Anatomy 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161561525P | 2011-11-18 | 2011-11-18 | |
| US61/561,525 | 2011-11-18 | ||
| PCT/US2012/065735 WO2013075068A1 (en) | 2011-11-18 | 2012-11-18 | Polymer protein microparticles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149732A Division JP6549653B2 (ja) | 2011-11-18 | 2017-08-02 | ポリマータンパク質微粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533698A JP2014533698A (ja) | 2014-12-15 |
| JP2014533698A5 true JP2014533698A5 (enExample) | 2016-01-07 |
| JP6267649B2 JP6267649B2 (ja) | 2018-01-24 |
Family
ID=47295198
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542536A Active JP6267649B2 (ja) | 2011-11-18 | 2012-11-18 | ポリマータンパク質微粒子 |
| JP2017149732A Active JP6549653B2 (ja) | 2011-11-18 | 2017-08-02 | ポリマータンパク質微粒子 |
| JP2019079952A Active JP6727372B2 (ja) | 2011-11-18 | 2019-04-19 | ポリマータンパク質微粒子 |
| JP2020112359A Active JP7217247B2 (ja) | 2011-11-18 | 2020-06-30 | ポリマータンパク質微粒子 |
| JP2023007775A Active JP7542090B2 (ja) | 2011-11-18 | 2023-01-23 | ポリマータンパク質微粒子 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149732A Active JP6549653B2 (ja) | 2011-11-18 | 2017-08-02 | ポリマータンパク質微粒子 |
| JP2019079952A Active JP6727372B2 (ja) | 2011-11-18 | 2019-04-19 | ポリマータンパク質微粒子 |
| JP2020112359A Active JP7217247B2 (ja) | 2011-11-18 | 2020-06-30 | ポリマータンパク質微粒子 |
| JP2023007775A Active JP7542090B2 (ja) | 2011-11-18 | 2023-01-23 | ポリマータンパク質微粒子 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20130129830A1 (enExample) |
| EP (4) | EP3384903B1 (enExample) |
| JP (5) | JP6267649B2 (enExample) |
| KR (4) | KR20210021112A (enExample) |
| CN (2) | CN103957898B (enExample) |
| AU (1) | AU2012340107B2 (enExample) |
| BR (1) | BR112014011915B1 (enExample) |
| CA (2) | CA2855749C (enExample) |
| DK (3) | DK3384903T3 (enExample) |
| ES (4) | ES2985784T3 (enExample) |
| FI (1) | FI2790681T4 (enExample) |
| HU (2) | HUE048597T2 (enExample) |
| IL (4) | IL277958B2 (enExample) |
| MX (2) | MX362286B (enExample) |
| PL (3) | PL2790681T5 (enExample) |
| PT (2) | PT3574897T (enExample) |
| RU (2) | RU2768492C2 (enExample) |
| SG (2) | SG11201402152YA (enExample) |
| WO (1) | WO2013075068A1 (enExample) |
| ZA (4) | ZA201403379B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| ES2985784T3 (es) | 2011-11-18 | 2024-11-07 | Regeneron Pharma | Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| ES2981791T3 (es) * | 2015-12-16 | 2024-10-10 | Regeneron Pharma | Composiciones y métodos para fabricar micropartículas de proteína |
| PL3394093T3 (pl) | 2015-12-23 | 2022-05-16 | Modernatx, Inc. | Metody stosowania polinukleotydów kodujących ligand ox40 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| MA43587A (fr) | 2016-01-10 | 2018-11-14 | Modernatx Inc | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| EP3459529A1 (en) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Preparation of sustained release solid dosage forms comprising antibodies by spray drying |
| MX2020005170A (es) | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| JP2022523063A (ja) * | 2019-01-30 | 2022-04-21 | アムジエン・インコーポレーテツド | アフリベルセプトの属性、並びにその特性決定及び修飾方法 |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3158119A1 (en) * | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| WO2022115588A1 (en) * | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| CN115887760A (zh) * | 2022-11-21 | 2023-04-04 | 娜罗曼苏(杭州)医疗生物科技有限公司 | 一种注射用左旋聚乳酸制备工艺 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2026080597A1 (en) * | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4210529A (en) | 1974-12-26 | 1980-07-01 | Midwest Research Institute | Blood compatible polymers and applications thereof |
| US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
| US4764364A (en) | 1986-02-25 | 1988-08-16 | S R I International | Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product |
| US5104221A (en) | 1989-03-03 | 1992-04-14 | Coulter Electronics Of New England, Inc. | Particle size analysis utilizing polarization intensity differential scattering |
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| US6063910A (en) | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
| ES2107051T3 (es) | 1992-09-21 | 1997-11-16 | Upjohn Co | Formulaciones de proteinas de liberacion sostenida. |
| GB9415810D0 (en) * | 1994-08-04 | 1994-09-28 | Jerrow Mohammad A Z | Composition |
| DE69534701T2 (de) | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | Verfahren zur behandlung von entzündlichen gelenkerkrankungen |
| US6004549A (en) | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| EP0913177A1 (de) | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung |
| DE69916031T2 (de) | 1998-01-29 | 2005-02-17 | Poly-Med Inc. | Asorbierbare mikropartikel |
| US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6223455B1 (en) * | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| AU1226901A (en) | 1999-10-22 | 2001-05-08 | Amgen, Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
| FR2809309B1 (fr) | 2000-05-23 | 2004-06-11 | Mainelab | Microspheres a liberation prolongee pour administration injectable |
| CA2418960A1 (en) | 2000-08-07 | 2002-02-14 | Inhale Therapeutic Systems, Inc. | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
| NZ530700A (en) | 2001-06-21 | 2009-02-28 | Altus Pharmaceuticals Inc | Spherical protein particles and methods of making and using them |
| US20040142043A1 (en) * | 2001-07-09 | 2004-07-22 | Atsushi Maeda | Sustained-release compositions for injection and process for producing the same |
| US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| RU2357750C2 (ru) | 2002-12-31 | 2009-06-10 | Элтус Фармасьютикалз Инк. | Кристаллы человеческого гормона роста и способы их получения |
| US20040208928A1 (en) * | 2003-04-15 | 2004-10-21 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
| JP5628467B2 (ja) | 2003-06-26 | 2014-11-19 | シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． | 生体分解性徐放性ドラッグデリバリーシステム |
| DE10339197A1 (de) | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| ES2286674T3 (es) * | 2003-10-01 | 2007-12-01 | Debio Recherche Pharmaceutique S.A. | Dispositivo y procedimiento para la fabricacion de particulas. |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| CA2576519C (en) | 2004-08-17 | 2013-05-21 | Regeneron Pharmaceuticals, Inc. | Il-1 antagonist formulations |
| US7572893B2 (en) | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| MX2007006214A (es) | 2004-11-24 | 2008-04-16 | Therakine Ltd | Un implante para suministro de farmaco intraocular. |
| WO2006071102A1 (en) | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| ES2616296T3 (es) | 2005-12-02 | 2017-06-12 | (Osi) Eyetech, Inc. | Micropartículas de liberación controlada |
| KR100722607B1 (ko) * | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| DE102006030166A1 (de) * | 2006-06-29 | 2008-01-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tempern |
| DE102006030164A1 (de) | 2006-06-29 | 2008-01-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Pulver |
| EP1958622A1 (en) | 2006-11-07 | 2008-08-20 | Royal College of Surgeons in Ireland | Method of producing microcapsules |
| US20100318193A1 (en) | 2007-03-08 | 2010-12-16 | Desai Tejal A | Topographically engineered structures and methods for using the same in regenerative medicine applications |
| EP3000434A1 (en) | 2007-03-16 | 2016-03-30 | The Regents Of The University Of California | Nanostructure surface coated medical implants and methods of using the same |
| KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
| CA2690858A1 (en) * | 2007-06-07 | 2008-12-18 | Surmodics Pharmaceuticals, Inc. | Reduced-mass, long-acting dosage forms |
| JP5773651B2 (ja) | 2007-12-21 | 2015-09-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 内部固形コア中に成長ホルモンを含有する固形脂質マイクロカプセル |
| CA2711984A1 (en) * | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| AU2010208046B2 (en) | 2009-01-29 | 2014-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| EP2411137B1 (en) * | 2009-03-27 | 2016-09-07 | Bend Research, Inc. | Spray-drying process |
| CN101559041B (zh) | 2009-05-19 | 2014-01-15 | 中国科学院过程工程研究所 | 粒径均一的多肽药物缓释微球或微囊制剂及制备方法 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| US8417452B2 (en) | 2009-08-19 | 2013-04-09 | General Motors Llc | System for providing information to an operator of a vehicle |
| KR20120095371A (ko) * | 2009-10-01 | 2012-08-28 | 에보닉 데구사 코포레이션 | 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| CN103209664A (zh) | 2010-08-05 | 2013-07-17 | 弗赛特影像4股份有限公司 | 可植入的治疗装置 |
| EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| CA2833144C (en) | 2011-04-14 | 2020-09-29 | The Regents Of The University Of California | Multilayer thin film drug delivery device and methods of making and using the same |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2985784T3 (es) | 2011-11-18 | 2024-11-07 | Regeneron Pharma | Micropartículas de proteínas recubiertas con polímeros para formulaciones de liberación prolongada para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares |
| EP2849723B1 (en) | 2012-05-18 | 2018-05-02 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
| CA2875146C (en) | 2012-05-30 | 2022-03-22 | The Regents Of The University Of California | Bioactive agent delivery devices and methods of making and using the same |
| WO2014039964A2 (en) | 2012-09-10 | 2014-03-13 | The Regents Of The University Of California | Compounds and methods for modulating vascular injury |
| EP2976107B1 (en) | 2013-03-19 | 2019-02-20 | ASIT BioTech s.a. | Allergen preparation |
| CA2954773C (en) | 2014-07-14 | 2023-10-03 | Amgen Inc. | Crystalline antibody formulations |
| EP3362041B1 (en) | 2015-10-16 | 2026-04-08 | Regeneron Pharmaceuticals, Inc. | Stable protein compositions |
| MX2018005388A (es) | 2015-11-05 | 2018-08-16 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatogenos. |
| AU2016352813B2 (en) | 2015-11-13 | 2019-09-19 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| US20170158901A1 (en) | 2015-12-07 | 2017-06-08 | Celanese International Corporation | Cellulose acetate film forming compositions |
| US20180339983A1 (en) | 2015-12-15 | 2018-11-29 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| ES2981791T3 (es) | 2015-12-16 | 2024-10-10 | Regeneron Pharma | Composiciones y métodos para fabricar micropartículas de proteína |
-
2012
- 2012-11-18 ES ES22150172T patent/ES2985784T3/es active Active
- 2012-11-18 SG SG11201402152YA patent/SG11201402152YA/en unknown
- 2012-11-18 PL PL12795967.4T patent/PL2790681T5/pl unknown
- 2012-11-18 MX MX2014005997A patent/MX362286B/es active IP Right Grant
- 2012-11-18 DK DK18173299.1T patent/DK3384903T3/da active
- 2012-11-18 ES ES12795967T patent/ES2775104T5/es active Active
- 2012-11-18 PT PT191803519T patent/PT3574897T/pt unknown
- 2012-11-18 DK DK19180351.9T patent/DK3574897T3/da active
- 2012-11-18 EP EP18173299.1A patent/EP3384903B1/en active Active
- 2012-11-18 RU RU2018101248A patent/RU2768492C2/ru active
- 2012-11-18 KR KR1020217004470A patent/KR20210021112A/ko not_active Ceased
- 2012-11-18 SG SG10202103003RA patent/SG10202103003RA/en unknown
- 2012-11-18 JP JP2014542536A patent/JP6267649B2/ja active Active
- 2012-11-18 AU AU2012340107A patent/AU2012340107B2/en active Active
- 2012-11-18 HU HUE12795967A patent/HUE048597T2/hu unknown
- 2012-11-18 IL IL277958A patent/IL277958B2/en unknown
- 2012-11-18 PL PL19180351T patent/PL3574897T3/pl unknown
- 2012-11-18 CA CA2855749A patent/CA2855749C/en active Active
- 2012-11-18 BR BR112014011915-5A patent/BR112014011915B1/pt active IP Right Grant
- 2012-11-18 ES ES18173299T patent/ES2810003T3/es active Active
- 2012-11-18 CN CN201280056324.6A patent/CN103957898B/zh active Active
- 2012-11-18 KR KR1020147014549A patent/KR102133352B1/ko active Active
- 2012-11-18 HU HUE18173299A patent/HUE051644T2/hu unknown
- 2012-11-18 CA CA3076725A patent/CA3076725A1/en active Pending
- 2012-11-18 RU RU2014124682A patent/RU2642664C2/ru active
- 2012-11-18 IL IL303832A patent/IL303832A/en unknown
- 2012-11-18 CN CN201610035281.3A patent/CN105688188A/zh active Pending
- 2012-11-18 WO PCT/US2012/065735 patent/WO2013075068A1/en not_active Ceased
- 2012-11-18 EP EP22150172.9A patent/EP4026543B1/en active Active
- 2012-11-18 EP EP19180351.9A patent/EP3574897B1/en active Active
- 2012-11-18 PT PT181732991T patent/PT3384903T/pt unknown
- 2012-11-18 US US13/680,069 patent/US20130129830A1/en not_active Abandoned
- 2012-11-18 FI FIEP12795967.4T patent/FI2790681T4/fi active
- 2012-11-18 ES ES19180351T patent/ES2909777T3/es active Active
- 2012-11-18 DK DK12795967.4T patent/DK2790681T4/da active
- 2012-11-18 PL PL18173299T patent/PL3384903T3/pl unknown
- 2012-11-18 KR KR1020207003704A patent/KR102218223B1/ko active Active
- 2012-11-18 KR KR1020227014819A patent/KR20220063293A/ko active Pending
- 2012-11-18 EP EP12795967.4A patent/EP2790681B9/en active Active
-
2014
- 2014-04-29 IL IL232328A patent/IL232328B/en active IP Right Grant
- 2014-05-12 ZA ZA2014/03379A patent/ZA201403379B/en unknown
- 2014-05-16 MX MX2019000382A patent/MX2019000382A/es unknown
-
2017
- 2017-03-06 US US15/450,335 patent/US11291636B2/en active Active
- 2017-08-02 JP JP2017149732A patent/JP6549653B2/ja active Active
-
2018
- 2018-01-05 ZA ZA2018/00078A patent/ZA201800078B/en unknown
- 2018-10-28 IL IL262651A patent/IL262651B/en active IP Right Grant
-
2019
- 2019-04-19 JP JP2019079952A patent/JP6727372B2/ja active Active
-
2020
- 2020-02-05 ZA ZA2020/00742A patent/ZA202000742B/en unknown
- 2020-06-30 JP JP2020112359A patent/JP7217247B2/ja active Active
-
2022
- 2022-02-22 US US17/677,282 patent/US11951216B2/en active Active
-
2023
- 2023-01-23 JP JP2023007775A patent/JP7542090B2/ja active Active
-
2024
- 2024-01-30 ZA ZA2024/00983A patent/ZA202400983B/en unknown
- 2024-03-07 US US18/598,435 patent/US20240207194A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533698A5 (enExample) | ||
| JP7217247B2 (ja) | ポリマータンパク質微粒子 | |
| Su et al. | PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application | |
| De Geest et al. | Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection | |
| Chew et al. | Biomaterial‐based implantable devices for cancer therapy | |
| Bachelder et al. | Acetalated dextran: a tunable and acid-labile biopolymer with facile synthesis and a range of applications | |
| Miladi et al. | Particles from preformed polymers as carriers for drug delivery | |
| Zaric et al. | Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D, L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses | |
| JP6912377B2 (ja) | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 | |
| US11576862B2 (en) | Methods and compositions for preparing a silk microsphere | |
| Hu et al. | PEGylated-PLGA nanoparticles coated with pH-responsive tannic acid–Fe (III) complexes for reduced premature doxorubicin release and enhanced targeting in breast cancer | |
| Thomas et al. | Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles | |
| JP2023085470A (ja) | 治療剤送達のための血小板組成物及び方法 | |
| US11213490B2 (en) | Encapsulation-free controlled protein release system | |
| KR20160003212A (ko) | 면역 관용의 유도를 위한 특정된 약역학적 유효 수명을 갖는 면역억제제 및 항원의 전달 | |
| JP2014518200A5 (enExample) | ||
| KR20210138596A (ko) | 치료제의 안구 투여용 약물전달 조성물 및 이의 사용방법 | |
| Zarubova et al. | Biomaterial-based immunoengineering to fight COVID-19 and infectious diseases | |
| CN111601592A (zh) | 尼古丁纳米疫苗及其用途 | |
| JP2015515968A5 (enExample) | ||
| Albisa et al. | Polymeric nanomaterials as nanomembrane entities for biomolecule and drug delivery | |
| Debnath et al. | Potential application of bionanoparticles to treat severe acute respiratory syndrome coronavirus-2 infection | |
| Kunkel et al. | Injectable controlled‐release systems for the prevention and treatment of infectious diseases | |
| Su et al. | Complementary Effects of Porosigen and Stabilizer on the Structure of Hollow Porous Poly (lactic-co-glycolic acid) Microparticles | |
| Baxendale et al. | Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology |